first glp-1 approval GLP-1R Agonists for Weight Loss Novo Nordisk's CagriSema: First Fixed-Dose
Description
The good news is that early evidence on oral semaglutide suggests a potential advantage here: One study showed that oral semaglutide improved blood sugar and reduced body fat while not significantly affecting muscle mass in those with type 2 diabetes
They are in a position to offer ongoing guidance, support, and dietary counseling, managing concerns such as dehydration, decreased fiber intake, and low protein consumption
Use a fitness tracker or phone pedometer
Microdosing supports gradual adaptation rather than shock to the system
Brain Res 878:194198
